Given the effect of SPHK1 inhibitor on tumor cells and T cells, we hypothesized that administering PF543 along with anti‐PD‐1 antibody should improve anti‐PD‐1 therapy for ovarian cancer by increasing the antitumor responses of T cells. This evidence concerns the gene SPHK1 and ovarian cancer.